43 related articles for article (PubMed ID: 15271314)
1. Construction of the metabolic reprogramming-associated gene signature for clear cell renal cell carcinoma prognosis prediction.
Tai R; Leng J; Li W; Wu Y; Yang J
BMC Urol; 2023 Sep; 23(1):147. PubMed ID: 37715154
[TBL] [Abstract][Full Text] [Related]
2. The Clinical and Molecular Features in the VHL Renal Cancers; Close or Distant Relatives with Sporadic Clear Cell Renal Cell Carcinoma?
Cinque A; Minnei R; Floris M; Trevisani F
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358771
[TBL] [Abstract][Full Text] [Related]
3. Aryl Hydrocarbon Receptor Mechanisms Affecting Chronic Kidney Disease.
Curran CS; Kopp JB
Front Pharmacol; 2022; 13():782199. PubMed ID: 35237156
[TBL] [Abstract][Full Text] [Related]
4. Von Hippel-Lindau Disease: Current Challenges and Future Prospects.
Gläsker S; Vergauwen E; Koch CA; Kutikov A; Vortmeyer AO
Onco Targets Ther; 2020; 13():5669-5690. PubMed ID: 32606780
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group.
Oudard S; Elaidi R; Brizard M; Le Rest C; Caillet V; Deveaux S; Benoit G; Corréas JM; Benoudiba F; David P; Gaudric A; Hammel P; Joly D; Timsit MO; Méjean A; Richard S
Oncotarget; 2016 Dec; 7(51):85306-85317. PubMed ID: 27852035
[TBL] [Abstract][Full Text] [Related]
6. Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials.
Aboagye EO; Gilbert FJ; Fleming IN; Beer AJ; Cunningham VJ; Marsden PK; Visvikis D; Gee AD; Groves AM; Kenny LM; Cook GJ; Kinahan PE; Myers M; Clarke L;
Eur Radiol; 2012 Jul; 22(7):1465-78. PubMed ID: 22476502
[TBL] [Abstract][Full Text] [Related]
7. Metabolic features of clear-cell renal cell carcinoma: mechanisms and clinical implications.
Pinthus JH; Whelan KF; Gallino D; Lu JP; Rothschild N
Can Urol Assoc J; 2011 Aug; 5(4):274-82. PubMed ID: 21801687
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapies in renal cell cancer: recent developments in imaging.
van der Veldt AA; Meijerink MR; van den Eertwegh AJ; Boven E
Target Oncol; 2010 Jun; 5(2):95-112. PubMed ID: 20625845
[TBL] [Abstract][Full Text] [Related]
9. Functional imaging of renal cell carcinoma.
Lawrentschuk N; Davis ID; Bolton DM; Scott AM
Nat Rev Urol; 2010 May; 7(5):258-66. PubMed ID: 20448659
[TBL] [Abstract][Full Text] [Related]
10. Novel imaging modalities in gynecologic cancer.
Brooks RA; Powell MA
Curr Oncol Rep; 2009 Nov; 11(6):466-72. PubMed ID: 19840524
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors.
Kieran MW; Supko JG; Wallace D; Fruscio R; Poussaint TY; Phillips P; Pollack I; Packer R; Boyett JM; Blaney S; Banerjee A; Geyer R; Friedman H; Goldman S; Kun LE; Macdonald T;
Pediatr Blood Cancer; 2009 Feb; 52(2):169-76. PubMed ID: 19065567
[TBL] [Abstract][Full Text] [Related]
12. Clinical biomarkers of angiogenesis inhibition.
Brown AP; Citrin DE; Camphausen KA
Cancer Metastasis Rev; 2008 Sep; 27(3):415-34. PubMed ID: 18414993
[TBL] [Abstract][Full Text] [Related]
13. Promise and progress for functional and molecular imaging of response to targeted therapies.
Stephen RM; Gillies RJ
Pharm Res; 2007 Jun; 24(6):1172-85. PubMed ID: 17385018
[TBL] [Abstract][Full Text] [Related]
14. A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points.
O'Donnell A; Padhani A; Hayes C; Kakkar AJ; Leach M; Trigo JM; Scurr M; Raynaud F; Phillips S; Aherne W; Hardcastle A; Workman P; Hannah A; Judson I
Br J Cancer; 2005 Oct; 93(8):876-83. PubMed ID: 16222321
[TBL] [Abstract][Full Text] [Related]
15. Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome.
Jennens RR; Rosenthal MA; Lindeman GJ; Michael M
Urol Oncol; 2004; 22(3):193-6. PubMed ID: 15271314
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.
Kuenen BC; Tabernero J; Baselga J; Cavalli F; Pfanner E; Conte PF; Seeber S; Madhusudan S; Deplanque G; Huisman H; Scigalla P; Hoekman K; Harris AL
Clin Cancer Res; 2003 May; 9(5):1648-55. PubMed ID: 12738717
[TBL] [Abstract][Full Text] [Related]
17. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.
Rini BI; Jaeger E; Weinberg V; Sein N; Chew K; Fong K; Simko J; Small EJ; Waldman FM
BJU Int; 2006 Oct; 98(4):756-62. PubMed ID: 16827904
[TBL] [Abstract][Full Text] [Related]
18. Understanding the importance of smart drugs in renal cell carcinoma.
Patard JJ; Rioux-Leclercq N; Fergelot P
Eur Urol; 2006 Apr; 49(4):633-43. PubMed ID: 16481093
[TBL] [Abstract][Full Text] [Related]
19. [A case of renal cell carcinoma associated with von Hippel-Lindau disease and the necessity for family genetic diagnosis].
Nanri M; Uda M; Iguchi Y; Gouya N; Toma H; Kihara T
Hinyokika Kiyo; 1999 Nov; 45(11):755-8. PubMed ID: 10637737
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
